SHPG : Summary for Shire plc - Yahoo Finance

U.S. Markets closed

Shire plc (SHPG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
177.40-0.76 (-0.43%)
At close: 4:00PM EDT

177.42 0.02 (0.01%)
After hours: 4:23PM EDT

People also watch
JAZZALXNBMRNMNKREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close178.16
Open177.65
Bid176.81 x 200
Ask179.51 x 500
Day's Range176.63 - 178.08
52 Week Range161.09 - 209.22
Volume877,109
Avg. Volume1,032,786
Market Cap53.62B
Beta1.71
PE Ratio (TTM)142.83
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.91 (0.52%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.comyesterday

    Shire: Can It Pay Down Debt?

    Gimme Credit is taking drug maker Shire (SHPG) to task today, but not for the load of debt it piled onto its once pristine balance sheet when it acquired U.S. drug make Baxalta last year. Rather, analyst Carol Levenson complains that while company has made progress paying down its management still doesn’t know how to talk to bond investors. According to Levenson, Shire, which unveiled terms of its $32 billion purchase of the Baxter (BAX) spinoff in January 2016, has never released detailed plans for deleveraging its balance sheet.

  • Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
    Zacks5 days ago

    Shire (SHPG) Rare Disease Drug Gets Fast Track Designation

    Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).

  • Investopedia6 days ago

    Shire hTTP Drug Secures Fast Track Designation

    Shire is planning a late-stage study for its SHP655 drug to treat a rare enzyme deficiency.